Current Environment:

Warning

Recall Alert

There is a voluntary recall of some nasal sprays. Learn more

Summary

An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects with PAH Deficiency Previously Administered HMI 102

Conditions

Phenylketonuria, PAH Deficiency

Recruitment Status

Enrolling by invitation

Detailed Description

This Long-Term Follow Up Study will evaluate the safety and efficacy of PKU Subjects with PAH Deficiency Previously Administered HMI 102. Subjects will have already received a single dose of HMI-102 administered intravenously

Eligibility Criteria

Inclusion Criteria:

Subject was previously administered HMI 102.
Subject is able to understand the purpose and risks of the study and is willing to provide informed consent.
Subject is able to comply with all study procedures and long-term follow-up.

Exclusion Criteria:

Participation in the study is not in the subject's best interest, in the opinion of the Investigator.

Intervention

Intervention Type

Intervention Name

Genetic

HMI-102

Gender

All

Min Age

18 Years

Max Age

55 Years

Download Date

June 30, 2022

Principal Investigator

N/A

Primary Contact Information

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

Long-Term Follow Up Study of Subjects Previously Administered HMI 102 NCT04348708